Biodesix Closes Series D Financing
News Aug 30, 2012
The new capital will support commercialization activities for the Company’s first product VeriStrat®, a blood-based test that helps physicians guide treatment for patients with non-small cell lung cancer (NSCLC). Funding will also support clinical validation studies, product development, and ongoing collaborations with a number of biotechnology and pharmaceutical companies.
Scientists have long known that circulating tumor cells, rare cancer cells that are released into the bloodstream, have the potential to provide vital information about a person's specific cancer. Researchers have now created an effective mechanism to measure how these cells perform functions that drive the disease.READ MORE